<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100958</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000406002</org_study_id>
    <secondary_id>KUMC-HSC-9139-2</secondary_id>
    <nct_id>NCT00100958</nct_id>
  </id_info>
  <brief_title>Indole-3-Carbinol in Preventing Cancer in Healthy Participants</brief_title>
  <official_title>Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of indole-3-carbinol may prevent cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects and best dose of&#xD;
      indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in&#xD;
      healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of indole-3-carbinol in healthy participants.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these participants.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these participants.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effects of this drug on selected markers of sexual function in these&#xD;
           participants.&#xD;
&#xD;
        -  Determine the effects of this drug on markers of susceptibility to cancer in these&#xD;
           participants.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, dose-escalation study.&#xD;
      Participants at each dose level are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Participants receive a single dose of oral indole-3-carbinol on day 1.&#xD;
&#xD;
        -  Arm II: Participants receive a single dose of oral placebo on day 1. Cohorts of 3&#xD;
           participants receive escalating doses of indole-3-carbinol until the maximum tolerated&#xD;
           dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3&#xD;
           participants experiences dose-limiting toxicity. An additional cohort of 3 participants&#xD;
           is treated at the MTD.&#xD;
&#xD;
      Participants are followed on days 2, 3, and 6.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 participants (18 in arm I and 6 in arm II) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indole-3-carbinol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy participants&#xD;
&#xD;
               -  Non-smoker&#xD;
&#xD;
               -  No drug abuse, as determined by urine cotinine and baseline drug screen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.8 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 110 U/L&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 300 U/L&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Weight within 20% of ideal body weight by the Metropolitan Life table&#xD;
&#xD;
          -  No serious drug allergies&#xD;
&#xD;
          -  No arthritis&#xD;
&#xD;
          -  No acute, unstable, chronic, or recurring medical condition&#xD;
&#xD;
          -  No strict vegetarians&#xD;
&#xD;
          -  No diabetes&#xD;
&#xD;
          -  No evidence of an active malignancy&#xD;
&#xD;
          -  No other serious intolerance or allergies&#xD;
&#xD;
               -  Mild seasonal allergies allowed&#xD;
&#xD;
          -  No other serious acute or chronic illness&#xD;
&#xD;
          -  None of the following chronic conditions:&#xD;
&#xD;
               -  Headaches&#xD;
&#xD;
               -  Dysphoria&#xD;
&#xD;
               -  Fatigue&#xD;
&#xD;
               -  Dizziness&#xD;
&#xD;
               -  Blurred vision&#xD;
&#xD;
               -  Insomnia&#xD;
&#xD;
               -  Rhinorrhea&#xD;
&#xD;
               -  Nausea&#xD;
&#xD;
               -  Vomiting&#xD;
&#xD;
               -  Abdominal pain&#xD;
&#xD;
               -  Diarrhea&#xD;
&#xD;
               -  Constipation&#xD;
&#xD;
               -  Premenstrual syndrome&#xD;
&#xD;
          -  Cessation of menses within the past 10 days (menstruating women only)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent oral contraceptives allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 21 days since prior medications, herbal products, dietary supplements, or&#xD;
             high-dose vitamins&#xD;
&#xD;
          -  More than 3 months since prior investigational drugs&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent ingestion of cruciferous vegetables,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Broccoli&#xD;
&#xD;
               -  Cabbage, including coleslaw&#xD;
&#xD;
               -  Cauliflower&#xD;
&#xD;
               -  Bok-choy&#xD;
&#xD;
               -  Brussels sprouts&#xD;
&#xD;
               -  Collards&#xD;
&#xD;
               -  Kale&#xD;
&#xD;
               -  Kohlrabi&#xD;
&#xD;
               -  Mustard greens&#xD;
&#xD;
               -  Rutabaga&#xD;
&#xD;
               -  Turnip&#xD;
&#xD;
               -  Watercress&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent alcohol consumption&#xD;
&#xD;
          -  At least 48 hours since prior ingestion of grapefruit-containing foods and beverages&#xD;
&#xD;
          -  No concurrent chronic drug therapy&#xD;
&#xD;
          -  No other concurrent supplements, including dietary supplements, vitamins, herbal&#xD;
             products, or over-the-counter medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Reed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indole-3-carbinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

